Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does clozapine decrease smoking?

Jose de Leon1, Francisco J Diaz, Richard C Josiassen

  • 1Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA. jdeleon@uky.edu

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|June 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cooking skills intervention for long-term weight loss in young adults with intellectual disabilities: Rationale and design for a randomized trial.

Contemporary clinical trials·2026
Same author

Temporal RT-qPCR-Based Porcine Cardiac Molecular Profiling for Post-Mortem Interval Estimation: Predictive Modeling.

International journal of molecular sciences·2026
Same author

Comparison of pembrolizumab dosing regimens and incidence and severity of immune-related adverse effects: A retrospective, case-control study.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Prevalence and symptoms of post-COVID-19 syndrome in active-duty military personnel.

The American journal of the medical sciences·2026
Same author

Zinc Deficiency Disrupts Germ Cell Nest Breakdown During In Vitro Ovary Culture.

Molecular reproduction and development·2026
Same author

Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: A randomized controlled trial protocol.

Contemporary clinical trials·2026
Same journal

Altered dorsal striatal subregional connectivity associated with distinct executive function deficits in first-episode, drug-naïve major depressive disorder: Evidence from functional connectivity and granger causality analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Chronic pain and stress: unravelling the common neuroinflammatory, immune and endocrine mechanisms for novel therapeutic approaches.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Predicting anhedonia and negative cognitive processing changes after 8-week SSRIs treatment in depression from individual differential structural covariance network.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Mapping intrinsic neural timescale alterations in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
See all related articles

This study found no significant decrease in smoking among schizophrenia patients treated with clozapine, as measured by cotinine levels. Further research is needed to confirm if clozapine may slightly reduce smoking in some individuals.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Addiction Research

Background:

  • Smoking is highly prevalent in patients with schizophrenia.
  • Previous studies suggest clozapine may reduce smoking, particularly at higher plasma levels.
  • The current study aimed to rigorously investigate clozapine's effect on smoking in schizophrenia patients.

Purpose of the Study:

  • To evaluate the impact of clozapine treatment on smoking behavior in daily smokers with schizophrenia.
  • To determine if plasma cotinine levels, a biomarker for smoking, decrease during clozapine therapy.
  • To explore dose-dependent and level-dependent effects of clozapine on smoking.

Main Methods:

  • A double-blind trial involving 38 daily smokers with schizophrenia was conducted.
  • Plasma cotinine levels were measured at baseline (haloperidol) and during clozapine treatment.

Related Experiment Videos

  • Five distinct analyses examined smoking reduction across different clozapine doses and plasma concentrations.

    • Main Results:

    • No significant decrease in plasma cotinine levels was observed across any of the five analyses.
    • Clozapine treatment, at doses of 100, 300, or 600 mg/day, did not significantly affect smoking.
    • Analyses mimicking previous studies also failed to show a significant clozapine-induced reduction in smoking.

    Conclusions:

    • The study did not find evidence that clozapine significantly reduces smoking in patients with schizophrenia.
    • A small decrease in smoking cannot be entirely ruled out for some individuals.
    • Prospective longitudinal studies with repeated measurements are necessary to further investigate clozapine's potential modest effect on smoking.